Nelly Conus

A staggering 72% of clinical trials fail to meet enrolment goals, often due to inconvenient trial logistics for patients. Direct-to-patient (DTP) clinical trial supply offers a promising solution, bringing medications and trial materials directly to patients' but challenges remain.

This interactive workshop explores how AI can be harnessed to overcome these hurdles and empower a smoother, more patient-centred DTP experience.

Core Focus Areas:

• Defining the Landscape: We'll establish a clear understanding of AI and its role in DTP supply chains, ensuring everyone is on the same page.
• Conquering Challenges: Explore how AI can tackle common roadblocks, including improving supply chain visibility, navigating regulatory complexities, and determining the best model – fully DTP or a hybrid approach.
• Temperature Control with Precision: Discover AI-powered solutions for maintaining optimal temperature control throughout the DTP journey, safeguarding the integrity of sensitive medications.
• Empowering Health Equity: Learn how AI can be leveraged to remove barriers and ensure diverse patient populations have equitable access to DTP clinical trials.

FINDING NOVEL APPROACHES TO CORE CHALLENGES: BENCHMARKING SUCCESS IN OVERCOMING KEY OPERATION & STRATEGIC BARRIERS

How does it work? Choose a 45-minute discussion on a pressing clinical trial supply topic. Interact with your peers, identifying contemporary challenges and novel approaches to confronting them. Each roundtable is led by a subject matter expert.

Following the conclusion of the discussions, there will be a 30-minute feedback session, where the roundtable leaders will share the key findings that came out of their respective discussions.

The discussion groups are:

GROUP A: OPTIMIZING CLINICAL TRIAL SUPPLY THROUGH STRATEGIC PLANNING AND FORECASTING OF COMPARATORS & CO-MEDICATION

GROUP B: PATIENT CENTRICITY IN CLINICAL TRIAL SUPPLY, HOW ARE YOU DOING IT?

GROUP C: HOW TO MITIGATE THE ENVIRONMENTAL IMPACT OF DIRECT-TO-PATIENT?

GROUP D: HOW CAN WE GO FURTHER IN REDUCING WASTE ACROSS THE SUPPLY CHAIN?

GROUP E: CAN THE COMMUNICATION WITH CLINICAL AND REGULATORY TEAMS UNLOCKS EFFICIENCY AND OVERCOME BARRIERS?

GROUP F: THE CHALLENGES ASSOCIATED WITH LOCAL SOURCING OF COMMERICAL MEDICATIONS FOR CLINICAL TRAILS